![]() Lercanidipine hydrochloride structure
|
Common Name | Lercanidipine hydrochloride | ||
---|---|---|---|---|
CAS Number | 132866-11-6 | Molecular Weight | 648.188 | |
Density | N/A | Boiling Point | 712.5ºC at 760mmHg | |
Molecular Formula | C36H42ClN3O6 | Melting Point | 175-177ºC | |
MSDS | Chinese USA | Flash Point | 384.7ºC | |
Symbol |
![]() GHS06 |
Signal Word | Danger |
Use of Lercanidipine hydrochlorideLercanidipine hydrochloride is a calcium channel blocker of the dihydropyridine class.Target: Calcium ChannelLercanidipine is a calcium channel blocker of the dihydropyridine class, which works by relaxing and opening the blood vessels allowing the blood to circulate more freely around the body. Lercanidipine was effective and well-tolerated in patients with mild-to-moderate hypertension in the daily practice. The effectiveness and safety of the drug were independent of the degree of cardiovascular risk [1, 2]. |
Name | Lercanidipine Hydrochloride |
---|---|
Synonym | More Synonyms |
Description | Lercanidipine hydrochloride is a calcium channel blocker of the dihydropyridine class.Target: Calcium ChannelLercanidipine is a calcium channel blocker of the dihydropyridine class, which works by relaxing and opening the blood vessels allowing the blood to circulate more freely around the body. Lercanidipine was effective and well-tolerated in patients with mild-to-moderate hypertension in the daily practice. The effectiveness and safety of the drug were independent of the degree of cardiovascular risk [1, 2]. |
---|---|
Related Catalog | |
References |
Boiling Point | 712.5ºC at 760mmHg |
---|---|
Melting Point | 175-177ºC |
Molecular Formula | C36H42ClN3O6 |
Molecular Weight | 648.188 |
Flash Point | 384.7ºC |
Exact Mass | 647.276184 |
PSA | 113.69000 |
LogP | 8.13240 |
Vapour Pressure | 3.77E-20mmHg at 25°C |
Storage condition | 2-8°C |
Symbol |
![]() GHS06 |
---|---|
Signal Word | Danger |
Hazard Statements | H301 |
Precautionary Statements | P301 + P310 |
Personal Protective Equipment | Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges |
Hazard Codes | T: Toxic; |
Risk Phrases | R25 |
Safety Phrases | S36/37-S45 |
RIDADR | UN 2811 |
~95% Lercanidipine h... CAS#:132866-11-6 |
Literature: CF Pharma Ltd. Patent: EP1860102 A1, 2007 ; Location in patent: Page/Page column 1; 8; 15 ; |
~41% Lercanidipine h... CAS#:132866-11-6 |
Literature: GLENMARK PHARMACEUTICALS LIMITED Patent: WO2007/31865 A2, 2007 ; Location in patent: Page/Page column 22-23 ; |
~% Lercanidipine h... CAS#:132866-11-6 |
Literature: WO2008/107797 A2, ; Page/Page column 16 ; |
~88% Lercanidipine h... CAS#:132866-11-6 |
Literature: RECORDATI IRELAND LIMITED Patent: WO2008/15248 A1, 2008 ; Location in patent: Page/Page column 7 ; |
~% Lercanidipine h... CAS#:132866-11-6 |
Literature: WO2006/59332 A1, ; Example 3 ; |
Differences in lercanidipine systemic exposure when administered according to labelling: in fasting state and 15 minutes before food intake.
Eur. J. Clin. Pharmacol. 68(7) , 1043-7, (2012) The aim of this study was to compare the systemic exposure of lercanidipine (Zanidip) after oral administration in the fasted state and 15 min before food intake (meals) to investigate if the recommen... |
|
Rationale for the use of a fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipine/enalapril.
Clin. Drug Investig. 30(12) , 843-54, (2010) Hypertension, a significant factor in the development of cerebrovascular disorders, heart disease and renal failure, is a common disorder worldwide. Despite the availability of a wide range of antihyp... |
|
Lercanidipine rescues hippocampus pyramidal neurons from mild ischemia-induced delayed neuronal death in SHRSP.
Cell. Mol. Neurobiol. 31(4) , 561-7, (2011) Stroke-prone spontaneously hypertensive rats (SHRSPs) are vulnerable to ischemia and delayed neuronal death (DND) of hippocampus pyramidal cells when bilateral carotid arteries are occluded for only 1... |
Renovia |
Vasodip |
Carmen |
Lercadip |
Lercan |
Lercaton |
2-((3,3-diphenylpropyl)methylamino)-1,1-dimethylethyl methyl (4RS)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate monohydrochloride |
Lercapin |
Lerdip |
Cardiovasc |
Lercanidipine hydrochloride |
Corifeo |
Lercanidipine hydrochloride hemihydrate |
Lerkamen |
Zanicor |
1-[(3,3-Diphenylpropyl)(methyl)amino]-2-methylpropan-2-yl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride (1:1) |
Masnidipine hydrochloride |
REC 15-2375 |
1-[(3,3-Diphenylpropyl)(methyl)amino]-2-methyl-2-propanyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate hydrochloride (1:1) |
Lerzam |
MFCD07773089 |
3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester, hydrochloride (1:1) |
Zandip |
Zanidip |
Lercanidipine (hydrochloride) |